Alterity Therapeutics (ATHE) Receivables (2015 - 2025)

Alterity Therapeutics' Receivables history runs 10 years deep, the most recent figure standing at $2.5 million for Q2 2025.

• In Q2 2025, Receivables fell 5.32% year-over-year to $2.5 million; the TTM figure through Jun 2025 stood at $2.5 million (down 5.32% YoY), while the FY2025 annual figure was $2.5 million, down 5.32% from the prior year.
• Receivables was $2.5 million for Q2 2025 at Alterity Therapeutics, down from $2.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $3.4 million in Q2 2022 to a low of $43596.5 in Q2 2023.
• Historically, Receivables has averaged $2.4 million across 5 years, with a median of $2.7 million in 2024.
• The sharpest annual moves came in 2021 and 2023: Receivables soared 8095.97% in 2021, then sank 98.71% in 2023.
• A 5-year view of Receivables shows it stood at $3.3 million in 2021, then increased by 2.75% to $3.4 million in 2022, then tumbled by 98.71% to $43596.5 in 2023, then soared by 6009.58% to $2.7 million in 2024, then decreased by 5.32% to $2.5 million in 2025.
• The last three Receivables figures came in at $2.5 million (Q2 2025), $2.7 million (Q2 2024), and $43596.5 (Q2 2023), per Business Quant data.